Literature DB >> 12680141

Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma.

Mattias Hedman1, Henrik Arnberg, Johan Wernlund, Henrik Riska, Ola Brodin.   

Abstract

Mesothelioma is a rare disease with poor prognosis. Monitoring the effect of treatment is a problem and a serum marker might be of use for this purpose. We have studied three serum markers TPA, Hyaluronan and CA 125 in a limited material (11 patients) with the purpose of finding out if they might reflect treatment effect and/or indicate prognosis. The results in our material show that correspondence between initial TPA levels and survival seems to be better than corresponding data regarding Hyaluronan and CAI 25. Five patients show increasing serum levels of all three serum markers from first to last sample as the mesothelioma progressed according to consecutive CT scans. In three of these patients stable disease was followed by a decrease in the serum marker levels. Our results indicate that these three serum markers and mainly TPA might be useful as markers of disease progression and TPA for prediction of survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12680141

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  CA125 in ovarian cancer.

Authors:  Nathalie Scholler; Nicole Urban
Journal:  Biomark Med       Date:  2007-12       Impact factor: 2.851

Review 2.  The Role of Mesothelin Expression in Serous Ovarian Carcinoma: Impacts on Diagnosis, Prognosis, and Therapeutic Targets.

Authors:  Giovanna Giordano; Elena Ferioli; Alessandro Tafuni
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

Review 3.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

4.  Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.

Authors:  Kazuya Fukuoka; Kozo Kuribayashi; Shusai Yamada; Kunihiro Tamura; Chiharu Tabata; Takashi Nakano
Journal:  Mol Clin Oncol       Date:  2013-09-02

5.  Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma.

Authors:  Tadashi Sato; Yohei Suzuki; Takanori Mori; Masahiro Maeda; Masaaki Abe; Okio Hino; Kazuhisa Takahashi
Journal:  Cancer Med       Date:  2014-07-10       Impact factor: 4.452

Review 6.  Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.

Authors:  David T Arnold; Duneesha De Fonseka; Fergus W Hamilton; Najib M Rahman; Nick A Maskell
Journal:  Br J Cancer       Date:  2017-02-07       Impact factor: 7.640

7.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

8.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

9.  Clinical significance of serum CA125 in diffuse malignant mesothelioma.

Authors:  Xu Cheng; Hong-Feng Gou; Ji-Yan Liu; De-Yun Luo; Meng Qiu
Journal:  Springerplus       Date:  2016-03-24

Review 10.  Developing a deeper insight into reproductive biomarkers.

Authors:  Braira Wahid; Hamid Bashir; Muhammad Bilal; Khansa Wahid; Aleena Sumrin
Journal:  Clin Exp Reprod Med       Date:  2017-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.